Titlebook: Chemotherapy; Volume 8 Cancer Chem K. Hellmann,T. A. Connors Book 1976 Plenum Press, New York 1976 cancer.chemotherapy.kinetics.pharmacokin

付出

Pharmacokinetics of Futraful (FT-207) for Clinical Application,lear that FT-207 is a masked or transport form. Therefore although FT-207 itself shows a very week direct activity against tumor cells, after entering the body, FT-207 is activated to 5-FU and thus becomes a potent carcinostatic substance.

咯咯笑

過份艷麗

Life Prolongation of Mice Bearing Syngeneic Tumor, Leukemia P388 with the Streptococcal Preparationvitro with the method of electrophoretic mobility of macrophage. At the early stage of tumor development, the cell-mediated immune response of the host treated with OK-432 was kept stronger than that of the untreated one. However, at the advanced stage of tumor development, there was little differen

tangle

Prevention of Lymphoma Growth in Mice by a Covalent Drug-Carrier-Antibody Complex,f cytotoxic drugs in cancer therapy. This method of conjugation provides for a high degree of drug substitution without significant loss of antibody activity and with no loss of water solubility. Suppression of tumour growth in vivo, and tests in vitro show greater effectiveness of the drug-carrier-

側(cè)面左右

暫時中止

洞穴

高深莫測

打谷工具

Theoretical Bases for Designing Combination Therapy with Dibromodulcitol (DBD),human tumours and reasonable therapeutic results can only be reached by combinations of drugs. At present, however, selection of drugs and treatment schedules for combination treatment is mostly empirical. Experiments should therefore be done to help the selection of the appropriate drugs for combin

Conquest